IGC Pharma (IGC) shifts fiscal year-end to December 31 with 9‑month transition
Rhea-AI Filing Summary
IGC Pharma, Inc. is changing its fiscal year-end from March 31 to December 31, with the change effective on December 31, 2025. This adjustment aligns the company’s financial reporting with the standard calendar year, which can make its results easier to compare with many other public companies. To bridge the gap between the old and new year-end, IGC plans to file a transition annual report covering a nine-month period from April 1, 2025 through December 31, 2025, giving investors a complete view of operations during the changeover period.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On December 30, 2025, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025. As a result of the change, the Company intends to file a Transition Report on Form 10-K for the nine-month transition period from April 1, 2025, through December 31, 2025 (the “Transition Period”).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IGC PHARMA, INC. | ||
| Dated: January 2, 2026 | By: | /s/ Claudia Grimaldi |
| Name: | Claudia Grimaldi | |
| Title: | Principal Financial Officer and Vice President | |
2
FAQ
What fiscal year change did IGC (IGC) announce?
IGC Pharma, Inc. announced that it is changing its fiscal year-end from March 31 to December 31, effective December 31, 2025.
When does IGC’s new fiscal year-end become effective?
The new fiscal year-end of December 31 becomes effective on December 31, 2025.
What transition period will IGC report because of the fiscal year change?
The company plans to report a nine-month transition period covering April 1, 2025 through December 31, 2025.
How will IGC report its results for the transition period?
IGC intends to file a transition annual report for the nine-month period from April 1, 2025 through December 31, 2025.
Why might IGC change its fiscal year-end to December 31?
The filing states that IGC is changing its fiscal year-end to December 31, which aligns financial reporting with the calendar year and many other public companies, potentially simplifying comparisons.
Does the fiscal year change affect IGC’s current operations?
The disclosure focuses on a change in reporting period; it does not describe changes to IGC’s underlying business operations.
